Cargando…
Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma
Introduction: Gliosarcomas are clinically aggressive tumors, histologically distinct from glioblastoma. Data regarding the impact of extent of resection and post-operative adjuvant therapy on gliosarcoma outcomes are limited. Methods: Patients with histologically confirmed gliosarcoma diagnosed betw...
Autores principales: | Jin, Michael C., Liu, Elisa K., Shi, Siyu, Gibbs, Iris C., Thomas, Reena, Recht, Lawrence, Soltys, Scott G., Pollom, Erqi L., Chang, Steven D., Hayden Gephart, Melanie, Nagpal, Seema, Li, Gordon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078164/ https://www.ncbi.nlm.nih.gov/pubmed/32219069 http://dx.doi.org/10.3389/fonc.2020.00337 |
Ejemplares similares
-
Evaluating the Association Between the Extent of Resection and Survival in Gliosarcoma
por: Ahmed, Fahad I, et al.
Publicado: (2019) -
Stereotactic Radiosurgery for Brain Metastases in Patients With a Heterozygous Germline Ataxia Telangiectasia Mutated Gene
por: Hall, Jennifer C, et al.
Publicado: (2023) -
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012) -
BIMG-13. A NOVEL RADIOPHARMACEUTICAL ([(18)F]DASA-23) TO MONITOR PYRUVATE KINASE M2 INDUCED GLYCOLYTIC REPROGRAMMING IN GLIOBLASTOMA
por: Beinat, Corinne, et al.
Publicado: (2021) -
Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma
por: Hui, Caressa, et al.
Publicado: (2022)